



## ASX RELEASE

### APPENDIX 4D & HALF-YEAR FINANCIAL REPORT

**Melbourne, Australia, 31 January 2019:** [Sienna Cancer Diagnostics Ltd, \(ASX:SDX\)](#) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer-related tests, announces its financial results for the half-year ended 31 December 2018.

Sienna reported a net loss of \$901,323 (2017: \$1,379,482) for the reporting period. The result for the reporting period includes the refund received from the Research & Development Tax Incentive, \$443,605, and \$40,000 from the Export Market Development Grant. The equivalent revenue items for the 2017 financial year were not recorded during the comparative period, as they were received later in the 2018 financial year.

The Company ended the reporting period with a cash balance of \$6,683,787 (2017: \$3,563,501), following the receipt of approximately \$5.2 million (before expenses) in capital raised via a share placement to institutional and sophisticated investors and a rights issue offer to existing shareholders. The funding will accelerate the evaluation of new technologies for acquisition or in-license, a key strategic goal previously communicated by the company. Significant due diligence on potential opportunities was undertaken during the reporting period.

In August 2018, Shaanxi GaoYuan In Vitro Diagnostic Reagents Co. was appointed distribution agent for The People’s Republic of China. China represents a significant market opportunity for Sienna, with a population of approximately 1.4 billion and a rapidly growing healthcare market. More recently the Company announced the appointment of Mirax Corporation Ltd as distribution agent for South Korea and further appointments for additional markets are expected in the near term.

During the 6 months to 31 December 2018, Sienna continued to work with its existing distribution agents to build the market for the Company’s IVD test for the detection of hTERT.

ENDS.

#### For further information, please contact:

Matthew Hoskin, CEO  
Sienna Cancer Diagnostics  
[mhoskin@siennadiagnostics.com.au](mailto:mhoskin@siennadiagnostics.com.au)  
+61 3 8288 2141

Kyahn Williamson or Scott Newstead  
WE Buchan  
[sienna@we-buchan.com](mailto:sienna@we-buchan.com)  
+61 3 8866 1200





## **About Sienna Cancer Diagnostics**

Sienna Cancer Diagnostics Ltd is an Australian medical technology company with operations in the United States, Europe and Australia. Sienna's strengths lie in identifying novel technologies then developing and commercialising them to satisfy an unmet clinical / market need. The Company has demonstrated the utility of its product with the help of its global clinical partners. Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised for being used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna's first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the assay can be used for clinical diagnostic purposes by pathology laboratories. Clinical pathology laboratories in those regions may purchase the product for use as an in vitro diagnostic test for the presence of hTERT, a component of telomerase.

## **Forward Looking Statements**

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.



**SIENNA CANCER DIAGNOSTICS LIMITED**  
**ABN 74 099 803 460**  
**AND CONTROLLED ENTITIES**

**APPENDIX 4D**  
**HALF-YEAR REPORT**  
**FOR THE HALF-YEAR ENDED 31 DECEMBER 2018**

**1. Reporting Period**

Current Reporting Year - the half-year ended 31 December 2018  
 Previous Reporting Year - the half-year ended 31 December 2017

**2. Results for Announcement to the Market**

	<b>December 2018</b>	<b>December 2017</b>	<b>Change</b>	<b>Change</b>
	<b>(\$)</b>	<b>(\$)</b>	<b>(\$)</b>	<b>(%)</b>
Revenue from ordinary activities	274,917	267,826	7,091	2.6
Loss from ordinary activities after income tax attributable to members	(901,323)	(1,379,482)	478,159	34.7
Net loss after tax attributable to members	(901,323)	(1,379,482)	478,159	34.7
<b>Earnings Per Share</b>		<b>December 2018</b>	<b>December 2017</b>	
Basic earnings per share (cents)		(0.00)	(0.01)	
Diluted earnings per share (cents)		(0.00)	(0.01)	
<b>Net Tangible Asset Backing</b>		<b>December 2018</b>	<b>December 2017</b>	
Net tangible assets per share (cents)		0.03	0.02	

**3. Financial Results**

This report should be read in conjunction with any ASX announcements made by Sienna Cancer Diagnostics Limited in accordance with the continuous disclosure requirements arising under the Corporations Act 2001 and ASX Listing Rules.

The information provided in this report contains all the information required by ASX Listing Rule 4.2A.

For an explanation of the financial results reported above please refer to commentary provided in the Directors' Report attached to the Financial Report for the half-year ended 31 December 2018.

**4. Dividends**

No dividend has been declared in relation to the half-year ended 31 December 2018 and no dividend was declared in relation to the half-year ended 31 December 2017.

**5. Statement of profit or loss and other comprehensive income with notes**

Refer to attached financial report.

**6. Statement of financial position with notes**

Refer to attached financial report.

**7. Statement of changes in equity**

Refer to attached financial report.

**8. Statement of cash flows**

Refer to attached financial report.

**9. Segment results**

Refer to Note 7 of the financial report attached.

**10. Details of entities over which control has been gained or lost during the period**

No transactions during the reporting period impacted Sienna's control of any entities.

**11. Details of associates and joint venture entities**

The consolidated entity had no associates or joint venture entities during the half-year ended 31 December 2018 or the half-year ended 31 December 2017.

**12. Other factors**

Refer to attached financial report.

**13. Matters relating to the auditor's independent review report**

The attached financial report has been reviewed and the independent auditor's review report contained within is not subject to a qualification.

SIENNA CANCER DIAGNOSTICS LIMITED  
ABN 74 099 803 460

FINANCIAL REPORT FOR THE HALF-YEAR ENDED  
31 DECEMBER 2018

This half-year financial report is to be read in conjunction with the Annual Report for the year ended 30 June 2018.

**Contents**

Directors' Report	2
Auditor's Independence Declaration	4
Financial Report for the half-year ended 31 December 2018	
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	5
Condensed Consolidated Statement of Financial Position	6
Condensed Consolidated Statement of Changes in Equity	7
Condensed Consolidated Statement of Cash Flow	7
Notes to the Financial Statements	8
Directors' Declaration	12
Independent Auditor's Review	13

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

---

## DIRECTORS' REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

The Directors of Sienna Cancer Diagnostics Limited (Sienna or the Company) present the financial report of Sienna Cancer Diagnostics Ltd and its subsidiary (the Group) for the half-year ended 31 December 2018.

### Directors and Company Secretary

The names of the Directors and Company Secretary of Sienna in office at any time during or since the end of the half-year are:

Geoffrey Cumming	Independent Non-executive Chairman
David Earp	Independent Non-executive Director
Helen Fisher	Independent Non-executive Director
Carl Stubbings	Independent Non-executive Director
John Chiplin	Independent Non-executive Director (resigned 30 September 2018)
Tony Di Pietro	Company Secretary

### Principal Activities

Sienna is a medical technology company that develops and commercialises cancer-related in-vitro diagnostic tests which address unmet clinical needs. Sienna's target market is pathology laboratories worldwide. The first product developed and brought to market by Sienna is the first in-vitro diagnostic (IVD) test for detection of hTERT, a component of the biomarker telomerase.

During the reporting period the key areas of activity related to:

- a share placement to institutional and sophisticated investors, raising \$1.6 million (before expenses) of new capital via the issue of new ordinary shares
- a rights issue offer to existing shareholders, which raised \$3.6 million (before expenses) of new capital via the issue of new ordinary shares
- supporting existing distribution agents with sales efforts in the United States and Europe
- the commencement of a clinical study at Royal Melbourne Hospital investigating the utility of Sienna's IVD test in thyroid samples
- research into the expanded utility of Sienna's IVD test in other cancer types
- due diligence activities related to the evaluation of complementary technologies for acquisition or in-license
- the appointment of an exclusive distribution partner in China for Sienna's IVD test
- pursuing further distribution agreements for Sienna's IVD test in new geographical markets

### Review of Operations

#### Operating results

The Group reported a loss of \$901,323 for the half-year ended 31 December 2018 (2017: loss \$1,379,482). The result for the reporting period includes the refund received from the Research & Development Tax Incentive, \$443,605, and \$40,000 from the Export Market Development Grant. The equivalent revenue items for the 2017 financial year were not recorded during the comparative period, as they were received later in the 2018 financial year.

#### Product Revenue and Gross Profit

Product revenue of \$274,917 (2017: \$267,826) was reported for the half-year ended 31 December 2018, while gross profit was \$249,479 (2017: \$241,260).

#### Other Revenue

The Company received \$443,605 in November 2018 from the Research and Development Tax Incentive claim for the 2018 financial year. Sienna's claim for the 2017 financial year had not been submitted during the comparative period, as AusIndustry's assessment of an Advance Overseas Finding application had not been received.

Sienna received the first tranche of the Export Market Development Grant (EMDG) for the 2018 financial year, \$40,000, in October 2018. The grant for the 2017 financial year was received in the second half of the 2018 financial year.

Interest income increased to \$73,343, from \$38,499 reported in the comparative period, as a result of the new capital received via the institutional placement and rights issue offer completed in July and August 2018.

#### Operating Expenditures

Overall operating expenditures remained relatively constant over the reporting periods, \$1,707,750 for the half-year to 31 December 2018 (2017: \$1,659,241).

Administration expenditures reduced to \$273,664 (2017: \$358,334), with the comparative period including initial ASX listing fees of \$107,200. During the 6 months to 31 December 2018, a net amount of \$14,554 was paid for the initial listing fees of the new shares issued via the share placement and rights issue offer.

A total of \$163,094 was recorded for research and development expenditure (2017: \$63,205). During the reporting period the first clinical study evaluating the utility of Sienna's IVD test for a second cancer indication, thyroid, was initiated, and activities were undertaken to evaluate additional cancer diagnostic technologies for acquisition or in-license.

Insurance expenditure increased to \$95,584 (2017: \$77,643), with the comparative period including only 5 months of Directors and Officers insurance premium as an ASX listed company.

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

---

## DIRECTORS' REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

### *Issued Capital*

The Company raised further capital in July and August 2018, via a share placement to institutional and sophisticated investors and a rights issue offer to existing shareholders, increasing issued capital by (net) \$4,896,931 (2017: \$4,262,466).

### *Cash Flow*

Cash reserves at 31 December 2018 were \$6,683,787 (31 December 2017: \$3,563,501). The Company recorded a net increase in cash held at the end of the half-year of \$3,991,955 (2017: \$2,845,845), the result of the new capital raised during the half-year; financing activities contributed \$4,896,931 (2017: \$4,262,466). Net cash used in operating activities for the half-year totalled \$784,113 (2017: \$1,386,175), with cash received from the Research and Development Tax Incentive, \$443,605, and the EMDG, \$40,000, accounting for the significant differences between the reported periods.

### *After Balance Date Events*

There has been no other matter or circumstance which has arisen since 31 December 2018 that has significantly affected or may significantly affect:

- (a) The operations, in financial years subsequent to 31 December 2018, of the consolidated entity, or
- (b) The results of those operations, or
- (c) The state of affairs, in financial years subsequent to 31 December 2018, of the consolidated entity.

### *Auditors' Independence Declaration*

A copy of the auditors' independence declaration as required under s307C of the *Corporations Act 2001* is set out on page 4.

None of Sienna's officers are former partners or Directors of Sienna's auditor, Walker Wayland NSW Chartered Accountants.

This report is made in accordance with a resolution of the Directors.



**Geoffrey J Cumming**  
Non-executive Chairman

Melbourne, Australia  
Dated this 30<sup>th</sup> day of January 2019

**AUDITORS' INDEPENDENCE DECLARATION  
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001  
TO THE DIRECTORS OF SIENNA CANCER DIAGNOSTICS LIMITED**

We declare that, to the best of our knowledge and belief, during the half year period ended 31 December 2018 there have been:

- (i) no contraventions of the auditors' independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the review.



**Walker Wayland NSW**  
**Chartered Accountants**



**Wali Aziz**  
**Partner**

Dated this 30<sup>th</sup> day of January 2019, Sydney

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

## CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

	Note	Half-year	
		31 Dec 2018 \$	31 Dec 2017 \$
<b>REVENUE FROM ORDINARY ACTIVITIES</b>			
Product revenue		274,917	267,826
Cost of sales		(25,438)	(26,566)
<b>GROSS PROFIT</b>		<b>249,479</b>	<b>241,260</b>
<b>OTHER REVENUE</b>			
Grant income		40,000	-
Research and Development Tax Incentive		443,605	-
Interest income		73,343	38,499
		<b>556,948</b>	<b>38,499</b>
<b>OPERATING EXPENDITURES</b>			
Employee and contractor costs	2	(1,038,132)	(1,014,526)
Administration	2	(273,644)	(358,334)
Research and development		(163,094)	(63,205)
Insurance		(95,584)	(77,643)
Travel and meetings		(70,551)	(78,806)
Depreciation and amortisation	2	(66,434)	(66,140)
Other expenses from ordinary activities		(311)	(587)
		<b>(1,707,750)</b>	<b>(1,659,241)</b>
<b>LOSS BEFORE INCOME TAX</b>		<b>(901,323)</b>	<b>(1,379,482)</b>
Income tax expense		-	-
<b>TOTAL COMPREHENSIVE LOSS FOR THE HALF-YEAR</b>		<b>(901,323)</b>	<b>(1,379,482)</b>
<b>EARNINGS PER SHARE</b>			
Basic earnings per share (cents per share)		(0.00)	(0.01)
Diluted earnings per share (cents per share)		(0.00)	(0.01)

The accompanying notes form part of these financial statements

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

## CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2018

	Note	31 Dec 2018 \$	30 June 2018 \$
<b>CURRENT ASSETS</b>			
Cash and cash equivalents	3	6,683,787	2,691,141
Trade and other receivables		171,802	124,008
Inventories		1,571	15,919
Other assets		84,127	172,000
<b>TOTAL CURRENT ASSETS</b>		<b>6,941,287</b>	<b>3,003,068</b>
<b>NON-CURRENT ASSETS</b>			
Intangibles	4	2,223,355	2,239,435
Property, plant and equipment		27,814	28,174
<b>TOTAL NON-CURRENT ASSETS</b>		<b>2,251,169</b>	<b>2,267,609</b>
<b>TOTAL ASSETS</b>		<b>9,192,456</b>	<b>5,270,677</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables		166,285	314,360
Provisions		120,612	113,132
<b>TOTAL CURRENT LIABILITIES</b>		<b>286,897</b>	<b>427,492</b>
<b>NON-CURRENT LIABILITIES</b>			
Provisions		56,376	47,658
<b>TOTAL NON-CURRENT LIABILITIES</b>		<b>56,376</b>	<b>47,658</b>
<b>TOTAL LIABILITIES</b>		<b>343,273</b>	<b>475,150</b>
<b>NET ASSETS</b>		<b>8,849,183</b>	<b>4,795,527</b>
<b>EQUITY</b>			
Issued capital	5	25,906,428	21,009,497
Reserves		163,809	173,017
Accumulated losses		(17,221,054)	(16,386,987)
<b>TOTAL EQUITY</b>		<b>8,849,183</b>	<b>4,795,527</b>

The accompanying notes form part of these financial statements

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

## CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

	Issued Capital \$	Reserves \$	Accumulated Losses \$	Total \$
<b>BALANCE AT 1 JULY 2017</b>	16,747,019	132,762	(14,235,651)	2,644,130
Loss attributable to members	-	-	(1,379,482)	(1,379,482)
Share based payments expense	-	34,522	-	34,522
Shares issued (net of issue costs)	4,262,466	-	-	4,262,466
<b>BALANCE AT 31 DECEMBER 2017</b>	<u>21,009,485</u>	<u>167,284</u>	<u>(15,615,133)</u>	<u>5,561,636</u>
<b>BALANCE AT 1 JULY 2018</b>	21,009,497	173,017	(16,386,987)	4,795,527
Loss attributable to members	-	-	(901,323)	(901,323)
Share based payments expense	-	58,048	-	58,048
Write back share based payments expense (expired options)	-	(67,256)	67,256	-
Shares issued (net of issue costs)	4,896,931	-	-	4,896,931
<b>BALANCE AT 31 DECEMBER 2018</b>	<u>25,906,428</u>	<u>163,809</u>	<u>(17,221,054)</u>	<u>8,849,183</u>

## CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

	Half-year	
	31 Dec 2018 \$	31 Dec 2017 \$
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
Receipts from product income	289,799	365,760
Receipts from the Research and Development Tax Incentive and grants	483,605	-
Interest received	65,752	30,072
Payments to suppliers and employees	(1,625,734)	(1,782,007)
Net cash used in operating activities	<u>(786,578)</u>	<u>(1,386,175)</u>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of intangibles	(39,737)	(16,499)
Purchase of property, plant and equipment	(10,257)	(13,947)
Payment for capitalised development costs	-	-
Loans to other entities	(68,404)	-
Net cash used in investing activities	<u>(118,398)</u>	<u>(30,446)</u>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of ordinary shares	5,227,625	4,597,600
Payment of share issue costs	(330,694)	(335,134)
Net cash provided by financing activities	<u>4,896,931</u>	<u>4,262,466</u>
<b>NET INCREASE IN CASH HELD</b>	3,991,955	2,845,845
Cash and cash equivalent at beginning of the half-year	2,691,141	720,399
Effects of exchange rate changes on balance of cash held in foreign currencies	691	(2,743)
<b>CASH AND CASH EQUIVALENT AT END OF FINANCIAL PERIOD</b>	<u>6,683,787</u>	<u>3,563,501</u>

The accompanying notes form part of these financial statements

## NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

### NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### Accounting Policies

##### a. Basis of Preparation

These general purpose interim financial statements for the half-year reporting period ended 31 December 2018 have been prepared in accordance with requirements of the Corporations Act 2001 and Australian Accounting Standard AASB 134: Interim Financial Reporting. The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Sienna Cancer Diagnostics Limited and its controlled entities (referred to as the “consolidated entity” or “group”). As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 30 June 2018, together with any public announcements made during the following half-year.

These interim financial statements were authorised for issue on 30 January 2019.

##### b. Accounting Policies

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements.

The Group has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to their operations and effective for the current half-year.

#### ***AASB 15: Revenue from Contracts with Customers***

The Group has adopted AASB 15 which is effective for annual periods beginning on or after 1 January 2018. AASB 15 applies to all contracts with customers as well as non-monetary exchanges between entities in the same line of business to facilitate sales to customers and potential customers. The core principle of the Standard is that an entity recognises revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the goods or services. The Group’s accounting policies for its revenue streams as disclosed in the most recent annual report are consistent with the accounting policies adopted for this half year financial report. The application of AASB 15 has not had a significant impact on the financial position and/or the financial performance of the group. No adjustments have therefore been recognised in this half year financial report.

#### ***AASB 16: Leases***

The Group has not early-adopted AASB 16. AASB 16 applies to annual reporting periods beginning on or after 1 January 2019. When effective, this Standard will replace the current accounting requirements applicable to leases in AASB 117: Leases and related Interpretations. AASB 16 introduces a single lessee accounting model that eliminates the requirement for leases to be classified as operating or finance leases. These changes are disclosed in the most recent annual financial report.

The Group has undertaken a detailed assessment of the impact of AASB 16. Based on the Group’s preliminary assessment, the likely impact on first time adoption of this standard includes an increase in right to use assets and lease liabilities recognised in the statement of financial position of \$23,354 for 30 June 2020.

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

## NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2018

	Half-year	
	31 Dec 2018	31 Dec 2017
	\$	\$
<b>NOTE 2: LOSS FROM ORDINARY ACTIVITIES BEFORE INCOME TAX BENEFIT</b>		
Loss from ordinary activities before income tax benefit has been determined after charging the following items:		
Employee and contractor costs		
- Staff salaries and contractors	744,535	753,910
- Directors' fees	128,563	108,261
- Superannuation	66,988	63,035
- Share based payments expense	58,048	34,522
- Other employment expenses	39,998	54,798
Per Consolidated Statement of Profit or Loss	<u>1,038,132</u>	<u>1,014,526</u>
Administration		
- ASX listing and transaction fees	31,717	128,774
- Investor/public relations and advisory fees	115,362	97,474
- Share registry fees	6,423	8,244
- Rental expense on operating lease	32,455	31,830
- Other administration expenses	87,687	92,012
Per Consolidated Statement of Profit or Loss	<u>273,644</u>	<u>358,334</u>
Depreciation and amortisation		
- Depreciation of plant and equipment	9,872	9,713
- Amortisation of building improvements	745	2,078
- Amortisation of capitalised development expenditure	55,817	54,349
Per Consolidated Statement of Profit or Loss	<u>66,434</u>	<u>66,140</u>

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

## NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

	31 Dec 2018	30 June 2018
<b>NOTE 3: CASH AND CASH EQUIVALENTS</b>	<b>\$</b>	<b>\$</b>
Cash on hand	40	40
Cash at bank	383,747	991,101
Term deposits	*6,300,000	1,700,000
	<u>6,683,787</u>	<u>2,691,141</u>
* Term deposits are made up of 3 deposits:		
- \$1,200,000, maturing 29 January 2019, earning 2.64%		
- \$4,100,000, maturing 4 March 2019, earning 2.71%		
- \$1,000,000, maturing 27 March 2019, earning 2.72%		
 <b>NOTE 4: INTANGIBLE ASSETS</b>		
<b>CAPITALISED DEVELOPMENT EXPENDITURE</b>		
SCD-A7™		
- Employee and contractor costs	1,239,653	1,239,653
- External development expenses	835,257	835,257
- Other capitalised expenses	151,678	151,678
	<u>2,226,588</u>	<u>2,226,588</u>
Accumulated amortisation	(222,483)	(166,666)
	<u>2,004,105</u>	<u>2,059,922</u>
<b>INTELLECTUAL PROPERTY</b>		
Patents – at cost	214,176	174,789
Trademarks – at cost	5,074	4,724
Accumulated amortisation / impairment	-	-
	<u>219,250</u>	<u>182,213</u>
	<u>2,223,355</u>	<u>2,239,435</u>

<b>Movement in Carrying Amounts</b>	<b>Trademarks</b>	<b>Intellectual Property</b>	<b>Capitalised Development</b>	<b>Total</b>
		\$	\$	\$
Balance at the beginning of the half-year	4,724	174,789	2,059,922	2,239,435
Additions	350	39,387	-	39,737
Amortisation	-	-	(55,817)	(55,817)
Balance at the end of the half-year	<u>5,074</u>	<u>214,176</u>	<u>2,004,105</u>	<u>2,223,355</u>

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

## NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2018

	31 Dec 2018 No.	30 June 2018 No.	31 Dec 2018 \$	30 June 2018 \$
<b>NOTE 5: ISSUED CAPITAL (NET)</b>				
Ordinary shares fully paid	267,389,407	180,262,327	25,906,428	21,009,497
Balance at the beginning of the reporting period	180,262,327	157,274,327	21,009,497	16,747,019
Issued during the year	87,127,080	22,988,000	5,227,625	4,597,600
Equity raising expenses	-	-	(330,694)	(335,122)
Balance at the end of the reporting period	267,389,407	180,262,327	25,906,428	21,009,497

Ordinary shares are the only class of equity the Company has on issue. During the six months to 31 December 2018 Sienna raised further capital via a share placement to institutional and sophisticated investors and a rights issue offer to existing shareholders. A total of 87,127,080 shares were issued at 6 cents per share. In the comparative 12 month period the Company listed on the ASX, issuing 22,988,000 shares at 20 cents per share.

### NOTE 6: CONTINGENT ASSETS OR LIABILITIES

There were no contingent assets or liabilities at 31 December 2018 or 30 June 2018.

### NOTE 7: SEGMENT REPORTING

In accordance with Australian Accounting Standard AASB 8 Operating Segments, the Company has determined that it has one reporting segment, consistent with the manner in which the business is managed. This is the manner in which the chief operating decision maker receives information for the purpose of resource allocation and assessment of performance. The Group operates predominantly in one business and geographical segment being the research and development of cancer diagnostics in Victoria, Australia.

### NOTE 8: EVENTS SUBSEQUENT TO REPORTING DATE

There has been no other matter or circumstance which has arisen since 31 December 2018 that has significantly affected or may significantly affect:

- The operations, in financial periods subsequent to 31 December 2018, of the consolidated entity, or
- The results of those operations, or
- The state of affairs, in financial periods subsequent to 31 December 2018, of the consolidated entity.

# SIENNA CANCER DIAGNOSTICS LIMITED

A.B.N 74 099 803 460

---

## DIRECTORS' DECLARATION

The Directors declare that:

1. in the Directors' opinion, the attached financial statements and notes thereto are in accordance with the *Corporations Act 2001*, including compliance with accounting standards and provide a true and fair view of the financial position and performance of the consolidated entity.
2. In the Directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors made pursuant to s.303(5) of the *Corporations Act 2001*.



**Geoffrey J Cumming**  
Non-executive Chairman  
Melbourne, Australia

Dated this 30<sup>th</sup> day of January 2019

## Independent Auditors Review Report

To the members of Sienna Cancer Diagnostics Limited

### Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Sienna Cancer Diagnostics Limited and its Controlled Entity which comprises the consolidated statement of financial position as at 31 December 2018, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the Company and the entity it controlled at the half-year end or from time to time during the financial period.

### Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entities financial position as at 31 December 2018 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Sienna Cancer Diagnostics Limited ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## **Independence**

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.

## **Conclusion**

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Sienna Cancer Diagnostics Limited is not in accordance with the *Corporations Act 2001*, including:

- i. giving a true and fair view of Sienna Cancer Diagnostics Limited's financial position as at 31 December 2018 and of its performance for the half-year ended on that date; and
- ii. complying with Accounting Standard AASB 134: *Interim Financial Reporting* and the *Corporations Regulations 2001*

A handwritten signature in black ink that reads 'Walker Wayland NSW'.

**Walker Wayland NSW**  
**Chartered Accountants**

A handwritten signature in black ink, appearing to be 'Wali Aziz'.

**Wali Aziz**  
**Partner**

Dated this 30<sup>th</sup> day of January 2019, Sydney